By 2030, will the FDA approve any drug in combination with a checkpoint blockade therapy that substantially reduces immune escape?

Checkpoint blockade therapy (also called immune checkpoint inhibitors) is an cancer therapy that works (roughly speaking) by preventing the cancer from disabling the immune system. There's a list of major immune checkpoint inhibitors here:

A common issue with this kind of therapy is immune escape: the cancer mutates and escapes from the immune system in some other way, which makes the drug much less effective or even useless. You can read an overview of the topic here:

This market resolves YES if any combination therapy is approved that:

  • Reduces immune escape by >= 10 percentage points over the course of two years according to any metric in an associated publication.

  • Increases long term survival rates (2 years) by >=10 percentage points, it is reported (by the developers of the drug) that this is believed to be due to preventing immune escape, and there is no published direct measure of immune escape.

Get Ṁ600 play money
Sort by:

What is the definition of immune escape? The paper you linked seems to use the term to refer to any treatment failure. For example: "Primary escape occurs when patients who have not previously received a given treatment fail to respond, and secondary escape occurs when patients who have responded to a treatment stop responding. Little data regarding mechanisms of secondary escape to anti-PD-L1/PD-1 therapy are available, and it is unclear whether the mechanisms of secondary escape are distinct from those of primary escape. Primary escape from anti-PD-L1/PD-1 therapy may be mediated by the numerous immunosuppressive mechanisms."

In other words, we don't really know what causes escape, so it's just defined clinically by treatment failure. Wouldn't that mean that anything that improves the effectiveness of immunotherapy treatment is reducing immune escape? And if so, this question should immediately resolve yes, since there are numerous drugs that are given in combination with immunotherapy and increase its effectiveness.

I think you mean something more specific by immune escape, but I am doubtful there are any clear definitions of what you mean, so I worry this question is irreparably marred by this definitional problem.